Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02685332 · ClinicalTrials.gov registry record · Phase 1

Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA

A Phase 1 study of Early Stage Breast Cancer, sponsored by University of Texas Southwestern Medical Center.

Active
Registry status
Phase 1
Development phase
30
Enrollment target
2
Study locations

NCT02685332 is a Phase 1 study of Early Stage Breast Cancer that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 30 participants, below the 412-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02685332, a Phase 1 study of Early Stage Breast Cancer, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

Radiation, Stereotactic Body Radiation Therapy.

Conditions Studied

Interventions

  • RADIATION Stereotactic Radiation

Study Locations (2)

New York

  • NYU Winthrop Hospital - Mineola

Texas

  • The University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-03-31
Est. Completion 2026-06
Phase Phase 1

What the Registry Record Tells You About NCT02685332

The ClinicalTrials.gov registry entry for NCT02685332 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 21 other Early Stage Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Early Stage Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiation is the first listed.

NCT02685332 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Texas.

Frequently Asked Questions

What is clinical trial NCT02685332 about?

NCT02685332 is a clinical study titled "Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA". Radiation, Stereotactic Body Radiation Therapy.

What is the current status of trial NCT02685332?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2016-03-31. Estimated completion is 2026-06.

What conditions does trial NCT02685332 study?

This clinical trial studies the following conditions: Early Stage Breast Cancer.

What interventions are being tested in trial NCT02685332?

The interventions under investigation include: Stereotactic Radiation (RADIATION).

Who is sponsoring clinical trial NCT02685332?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02685332 being conducted?

This trial has 2 study locations across New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Early Stage Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.